Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity
Novartis presented long-term data from the NEPTUNUS extension study of ianalumab for Sjögren’s disease at ACR 2026. Continuous treatment showed sustained improvements in disease activity and salivary flow, with no new safety issues. Patients switching from placebo to ianalumab also saw benefits. The FDA decision is expected this year.
How this was made
The 30-second read
Why it matters
The extension data provide the first long‑term efficacy readout, likely influencing analyst forecasts and positioning ahead of the FDA decision.
Market read
New trial data could lift Novartis stock and affect biotech sector sentiment, especially for companies with similar mechanisms.
What to watch
Potential competition from other B‑cell therapies and the need for reimbursement approvals
Background
Novartis is a large, diversified Swiss pharmaceutical company with a US‑listed ticker (NVS). The ianalumab program targets multiple B‑cell driven diseases.
Ticker impact
Novartis presented new long‑term ianalumab Phase III extension data for Sjögren’s disease, showing continued efficacy and safety through Week 108.
potential upward pressure as market prices in improved efficacy and regulatory prospects
Data are first‑time disclosure, show deeper disease‑activity reductions and sustained safety, and precede an FDA decision expected this year.
Market effects
strengthens the autoimmune‑therapy pipeline, may lift peers developing B‑cell targeting drugs
positive for Swiss pharma sector and US biotech investors tracking FDA pipelines
adds to global biotech sentiment ahead of upcoming FDA reviews
Counterpoint
If the FDA delays or requires additional data, the short‑term rally could reverse
Key entities
- companyNovartis
Swiss pharma giant developing ianalumab
- drugianalumab
Monoclonal antibody for Sjögren’s disease and other autoimmune indications
